Strategic partnerships Proscia already collaborates with Imagene AI and has a broad customer base including 16 of the top 20 pharmaceutical companies and a global lab network. This indicates a strong openness to ecosystem integrations and co-development opportunities. A sales strategy could focus on expanding OEM and integration partnerships with complementary AI and imaging tools to broaden Concentriq adoption.

Enterprise validation Achieving top scores in KLAS Digital Pathology in both the US and Europe and having FDA 510(k) clearance plus CE-IVDR certification signals high credibility with healthcare buyers. Use these approvals in targeted pitches to large health systems and reference customers to shorten procurement cycles.

Gen AI enhancements The launch of the Fifth Generation Concentriq and the integration with AI-driven capabilities positions Proscia as a leader in advancing AI in pathology. This offers opportunities to upsell or cross-sell to existing customers seeking more automation, faster decision support, and scalable pathology workflows.

Financial growth With reported revenue in the mid tens of millions and substantial funding backing, Proscia demonstrates financial stability and capacity to invest in enterprise deployments. Use this to justify long-term contracts, multi-site expansions, and phased deployment strategies with risk-reducing financial terms.

Expansion opportunities Recent customer wins such as NextGen Pathology and a growing global customer base suggest continued expansion across regions and laboratories. Target regional networks, academic centers, and large pathology groups with tailored ROI cases focused on diagnostic accuracy, throughput, and drug development insights.